Ру O’z Ўзб Eng
+998 71 228-06-96

+998 78 120-16-61

1002
not found
Кенгайтирилган қидирув
    Press-service

    News

    not found

    WHO sounds alarm on viral hepatitis infections claiming 3500 lives each day

    According to the World Health Organization (WHO) 2024 Global Hepatitis Report, the number of lives lost due to viral hepatitis is increasing. The disease is the second leading infectious cause of death globally -- with 1.3 million deaths per year, the same as tuberculosis, a top infectious killer. The report, released at the World Hepatitis Summit, highlights that despite better tools for diagnosis and treatment, and decreasing product prices, testing and treatment coverage rates have stalled. But, reaching the WHO elimination goal by 2030 should still be achievable, if swift actions are taken now. New data from 187 countries show that the estimated number of deaths from viral hepatitis increased from 1.1 million in 2019 to 1.3 million in 2022. Of these, 83% were caused by hepatitis B, and 17% by hepatitis C. Every day, there are 3500 people dying globally due to hepatitis B and C infections. Updated WHO estimates indicate that 254 million people live with hepatitis B and 50 million with hepatitis C in 2022. Half the burden of chronic hepatitis B and C infections is among people 30–54 years old, with 12% among children under 18 years of age. Men account for 58% of all cases. New incidence estimates indicate a slight decrease compared to 2019, but the overall incidence of viral hepatitis remains high. In 2022, there were 2.2 million new infections, down from 2.5 million in 2019. These include 1.2 million new hepatitis B infections and nearly 1 million new hepatitis C infections. More than 6000 people are getting newly infected with viral hepatitis each day. The report outlines a series of actions to advance a public health approach to viral hepatitis, designed to accelerate progress towards ending the epidemic by 2030. They include: expanding access to testing and diagnostics; shifting from policies to implementation for equitable treatment; strengthening primary care prevention efforts; simplifying service delivery, optimizing product regulation and supply; developing investment cases in priority countries; mobilizing innovative financing; using improved data for action; and engaging affected communities and civil society and advancing research for improved diagnostics and potential cures for hepatitis B.

    • 18 April, 14:43
    • Read more
    not found

    Nigeria becomes first country to roll out new meningitis vaccine, WHO says

    Nigeria has become the first country in the world to roll out the "revolutionary" new Men5CV vaccine against meningitis, the World Health Organization (WHO) said. Nigeria is one of the hotspots of the deadly disease in Africa. Last year, a 50% rise in annual cases was reported across 26 African countries regarded as meningitis hyperendemic countries, according to the WHO. “Nigeria's rollout brings us one step closer to our goal to eliminate meningitis by 2030," Tedros Ghebreyesus, WHO Director General, was quoted as saying in a statement. Between last October and mid-March this year, 1,742 cases were suspected in the country, with 153 deaths recorded in seven states in Nigeria, data from the WHO shows. The new vaccine is reported to protect against the five major strains of the disease that are prevalent in Nigeria, unlike the initial vaccine that works against only one strain, said the WHO.

    • 15 April, 12:51
    • Read more
    not found

    Study links e-cigarette use with higher risk of heart failure

    People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date investigating possible links between vaping and heart failure. The findings are being presented at the American College of Cardiology's Annual Scientific Session. Heart failure is a condition affecting more than 6 million U.S. adults in which the heart becomes too stiff or too weak to pump blood as effectively as it should. It can often lead to debilitating symptoms and frequent hospitalizations as people age. Electronic nicotine products, which include e-cigarettes, vape pens, hookah pens, personal vaporizers and mods, e-cigars, e-pipes and e-hookahs, deliver nicotine in aerosol form without combustion. Since they were first introduced in the U.S. in the late 2000s, electronic nicotine products have often been portrayed as a safer alternative to smoking, but a growing body of research has led to increased concern about potential negative health effects. For the study, researchers used data from surveys and electronic health records in All of Us, a large national study of U.S. adults run by the National Institutes of Health, to analyze associations between e-cigarette use and new diagnoses of heart failure in 175,667 study participants (an average age of 52 years and 60.5% female). Of this sample, 3,242 participants developed heart failure within a median follow-up time of 45 months. The results showed that people who used e-cigarettes at any point were 19% more likely to develop heart failure compared with people who had never used e-cigarettes.

    • 4 April, 12:48
    • Read more
    not found

    10:03 / 01.04.2024

    Human brains are getting larger

    not found

    08:47 / 28.03.2024

    $4.25 million gene therapy for kids becomes world's priciest drug

    not found

    11:48 / 27.03.2024

    2 die, 100 hospitalized after consuming Japan drugmaker's supplements

    not found

    09:09 / 27.03.2024

    Trans fat. Key facts

    not found

    08:50 / 26.03.2024

    Millions at risk from cholera due to lack of clean water, soap and toilets, and shortage of cholera vaccine

    not found

    14:49 / 20.03.2024

    Over 1 in 3 people affected by neurological conditions

    Нажмите на кнопку ниже, чтобы прослушать текст Powered by GSpeech